Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1997 Nov-Dec;6(6):329-33.
doi: 10.1002/(SICI)1520-6661(199711/12)6:6<329::AID-MFM6>3.0.CO;2-Q.

Atrial natriuretic peptide in transient puerperal hypertension

Affiliations

Atrial natriuretic peptide in transient puerperal hypertension

K Nagai et al. J Matern Fetal Med. 1997 Nov-Dec.

Abstract

This study is the first approach to evaluate whether human atrial natriuretic peptide (hANP) is involved in the pathophysiology in transient puerperal hypertension (TPH). Five women who were normotensive throughout pregnancy, labor, and delivery developed hypertension between the first and sixth postpartum day. hANP (pg/ml) and plasma renin activity (PRA, ng/ml/h), angiotensin I, II (AI, II, pg/ml), and aldosterone (Aldo, pg/ml) in plasma were quantified by radioimmunoassay. Ten women without hypertension were also studied on hANP, PRA, AI, AII, and Aldo sequentially as the control group. hANP was apparently lower in women with TPH than in normotensive women. The levels of PRA, AI, AII, and Aldo were also clearly decreased in women with TPH, whereas those values in normotensive women were not altered from nonpregnant levels. Maternal natriuresis usually reaches the peak at 3-5 days postpartum. The decrease of hANP and PPA, AI, AII, and Aldo in TPH coincides with this natriuretic period. This observation suggests that hANP may serve an important role in the pathogenesis of TPH.

PubMed Disclaimer

LinkOut - more resources